Arthritis, Rheumatoid Clinical Trial
— LEADEROfficial title:
Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients
Verified date | October 2010 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Czech Republic: Ethics Committee |
Study type | Interventional |
To assess the efficacy response rate at 3-months of two dosing regimen of leflunomide in
DMARDs-naive patients presenting an early-RA using American College of Rheumatology 20%
response rate.
To assess the clinical efficacy at 1-month and 3-month using complementary efficacy criteria
(ACR 50, ACR 70, DAS 28) in each group of treatment, To assess the clinical and biological
safety using standard blood monitoring, TEAED and SAE in each group of treatment, To
evaluate treatment modifications; particularity leflunomide and concomitant use of AINS and
corticoids.
Status | Completed |
Enrollment | 124 |
Est. completion date | October 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of active rheumatoid arthritis in the previous 6 months (according to the ACR guidelines) - Must have active disease to be initiated by DMARDs (Disease Modifying Anti-Rheumatic Drugs) Exclusion Criteria: - Patient presenting or having a history of other inflammatory joint disease - Patient with ongoing or previous Stevens-Johnson syndrome, toxic epidermal necrolysis or erythema multiforme - Patient with significantly impaired bone marrow function or significant anaemia, leucopenia or thrombocytopenia due to causes or other than active rheumatoid arthritis - Persistent infection or severe infection within 3 months before enrollment, - Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, terminal illness or other medical condition which, in the opinion of the investigator, would put the patient at risk to participate in the study, - Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult - Severe hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin < 3.0 g/dl - Moderate or severe impairment of renal function, as known by serum creatinine > 133 mcmol/L (or 1.5 mg/dl) - Patient with history of recent and clinically significant drug or alcohol abuse - Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold the upper limit of normal - Pregnancy - Breastfeeding - Women of childbearing potential, except if they fulfill specific conditions, - Men wishing to father children during the course of the study or within the 24 months thereafter (or 3 month with the washout procedure) - Patient with a congenital or acquired severe immuno-deficiency, a history of cancer or lymphoproliferative disease, or any patient who has received total lymphoid irradiation - Known HIV positive status - Known positive serology for hepatitis B or C - Patient with hypersensitivity to any of the excipients in the tablets of leflunomide - Previous therapy at any time with: - any DMARD including methotrexate, oral or injectable gold salts, chloroquine, hydroxychloroquine, ciclosporin, azathioprine, methotrexate, sulfasalazine - D penicillamine - alkylating agents, e.g., cyclophosphamide, chlorambucil, biological agents, e.g., interferon, monoclonal antibodies, growth factor, cytokines - any investigational drug - any antimetabolites - any opiates - Therapy within the previous 4 weeks with: - oral corticosteroids exceeding a prednisolone equivalent of 10 mg/day - parenteral or intra-articular corticoid injection The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Czech Republic | Sanofi-Aventis Administrative Office | Praha | |
Italy | Sanofi-Aventis Administrative Office | Milan | |
Korea, Republic of | Sanofi-Aventis Administrative Office | Seoul | |
Portugal | Sanofi-Aventis Administrative Office | Porto Salvo | |
Romania | Sanofi-Aventis Administrative Office | Bucuresti |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Czech Republic, Italy, Korea, Republic of, Portugal, Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical efficacy response rate using ACR 20 criteria in each initial dosing regimen group | at 3 month | No | |
Secondary | Clinical efficacy response rate using ACR 50, ACR 70, DAS 28 efficacy criteria in each group of treatment | at 1 and 3 months | No | |
Secondary | Clinical and biological safety using standard blood monitoring, TEAED and SAE in each group of treatment | From the Informed Consent Form (ICF) signature to the end of the study | No | |
Secondary | Measure of acute phase response (ESR, CRP) | At 1 and 3 months | No | |
Secondary | Patient and physician global assessment | At 1 and 3 months | No | |
Secondary | SF-36 questionnaire | At 1 and 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |